Dehydroepiandrosterone-dependent induction of peroxisomal proliferation can be reduced by aspartyl esterification without attenuation of inhibitory bone loss in ovariectomy animal model.
10.3346/jkms.2000.15.5.533
- Author:
Chung Shil KWAK
1
;
Chang Mo KANG
;
Heun Soo KANG
;
Kye Yong SONG
;
Mee Sook LEE
;
Sang Cheol SEONG
;
Sang Chul PARK
Author Information
1. Aging and Physical Culture Research Institute, Seoul National University, Korea. kwakcs@snu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Dehydroepiandrosterone;
Aspartic Acid;
Osteoporosis;
Peroxisomal Proliferation;
Ovariectomy
- MeSH:
Adjuvants, Immunologic/pharmacology*;
Adjuvants, Immunologic/metabolism;
Adjuvants, Immunologic/chemistry;
Animal;
Aspartic Acid/pharmacology*;
Aspartic Acid/metabolism;
Aspartic Acid/chemistry;
Biological Markers;
Calcium/urine;
Calcium/blood;
Disease Models, Animal;
Esterification;
Fatty Acid Desaturases/metabolism;
Female;
Injections, Intraperitoneal;
Lipoproteins, HDL Cholesterol/blood;
Lipoproteins, LDL Cholesterol/blood;
Liver/enzymology;
Liver/drug effects;
Organ Weight;
Osteoporosis/pathology;
Osteoporosis/metabolism*;
Osteoporosis/drug therapy*;
Ovariectomy*;
Peroxisomes/metabolism*;
Prasterone/pharmacology*;
Prasterone/metabolism;
Prasterone/chemistry;
Rats;
Rats, Sprague-Dawley;
Tibia/pathology;
Tibia/metabolism;
Triglycerides/blood
- From:Journal of Korean Medical Science
2000;15(5):533-541
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this study was to determine whether esterification of dehydroepiandrosterone with aspartate (DHEA-aspartate) could reduce peroxisomal proliferation induced by DHEA itself, without loss of antiosteoporotic activity. Female Sprague-Dawley rats were ovariectomized, then DHEA or DHEA-aspartate was administered intraperitoneally at 0.34 mmol/kg BW 3 times a week for 8 weeks. DHEA-aspartate treatment in ovariectomized rats significantly increased trabeculae area in tibia as much as DHEA treatment. Urinary Ca excretion was not significantly increased by DHEA or DHEA-aspartate treatment in ovariectomized rats, while it was significantly increased by ovariectomy. Osteocalcin concentration and alkaline phosphatase activity in serum and cross linked N-telopeptide type I collagen level in urine were not significantly different between DHEA-aspartate and DHEA treated groups. DHEA-aspartate treatment significantly reduced liver weight and hepatic palmitoyl-coA oxidase activity compared to DHEA treatment. DHEA-aspartate treatment maintained a nearly normal morphology of peroxisomes, while DHEA treatment increased the number and size of peroxisomes in the liver. According to these results, it is concluded that DHEA-aspartate ester has an inhibitory effect on bone loss in ovariectomized rats with a marked reduction of hepatomegaly and peroxisomal proliferation compared to DHEA.
